Exicure Inc (NASDAQ: XCUR) is a biotechnology company that historically developed nucleic acid therapies targeting ribonucleic acid but suspended all research and development activities in September 2022. The company generates minimal revenue through licensing agreements tied to its legacy patent portfolio, having received a $500,000 upfront payment in February 2024 from a licensing agreement for patents related to one historical drug candidate, along with entitlement to modest royalties. As of the 10-K filed March 25, 2026, Exicure is also party to a License and Collaboration Agreement with GPCR USA, whose Phase 2 clinical trial in blood cancer patients completed in January 2026, with Exicure committed to a $1,000,000 milestone payment to GPCR USA in shares of common stock in the second quarter of 2026. The company is headquartered in Chicago, Illinois, with Jung Soo Kim serving as Chief Executive Officer. Exicure reported net losses for both fiscal years 2024 and 2025 and carries no disclosed product revenue.

Revenue model

Licensing fees and royalties from legacy nucleic acid therapy patents. The company received a $500,000 upfront licensing payment in February 2024 and is entitled to modest royalties on one historical drug candidate. No product or collaboration revenue is disclosed for FY2025.

Products and services

Legacy nucleic acid therapy patent portfolio licensed to third parties. Collaboration with GPCR USA involving GPC-100 (a small molecule antagonist targeting a chemokine receptor) combined with propranolol for stem cell mobilization in Multiple Myeloma patients, with a Phase 2 clinical trial completed January 2026.

Customers and end markets

Licensees of nucleic acid therapy patents. End market exposure is to blood cancer and hematopoietic stem cell transplantation via the GPCR USA collaboration. No customer concentration data disclosed in the filing excerpts.

Value-chain role

Patent licensor for legacy drug development IP. Collaboration partner and milestone payer to GPCR USA for clinical-stage oncology assets. The company does not manufacture or commercialize products as of the filing date.

Geographic exposure

Headquartered in Chicago, Illinois. Formed a South Korean subsidiary, KC Creation Co., Ltd., in March 2025, which was subsequently sold in November 2025. No other geographic revenue breakdown disclosed.

Source: SEC 10-K, filed 2026-03-25

Industry: Pharmaceutical Preparations Peers: Bellerophon Therapeutics, Inc. Benitec Biopharma Inc TuHURA Biosciences Inc Cibus Inc Sonnet BioTherapeutics Holdings, Inc. CohBar, Inc. Ensysce Biosciences Inc Phio Pharmaceuticals Corp Unicycive Therapeutics Inc